Background Systemic lupus erythematosus (SLE) is an autoimmune disease that typically
affects women aged 16–55 years. Cardiovascular disease (CVD) is a well-recognized …

Systemic lupus erythematosus (SLE) often features extensive cardiovascular (CV)
comorbidity and patients with SLE are at significantly increased risk of CV event occurrence …

The contribution of dyslipidemia and inflammation in atherosclerosis is well established.
Along with effective lipid-lowering treatments, the recent success of clinical trials with anti …

Hydroxychloroquine (HCQ) and chloroquine (CQ) are well‐established medications used in
treating systemic lupus erythematosus and rheumatoid arthritis, as well as skin conditions …

Objectives The 2022 EULAR recommendations for cardiovascular risk management in
patients with rheumatic disorders, including SLE, call for rigorous management of …

Abstract Coronavirus disease 2019 (COVID‐19) is a novel pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). It has been shown that SARS …

Vascular disease is a major cause of morbidity and mortality in patients with systemic
autoimmune diseases, particularly systemic lupus erythematosus (SLE). Although comorbid …

Hydroxychloroquine (HCQ) has been shown to be at least somewhat effective in treating
patients with coronavirus disease 2019 (COVID-19). Recently the US Food and Drug …

Background Previous studies have shown that patients with systemic lupus erythematosus
(SLE) tend to have a higher risk of cardiovascular disease (CVD), but the potential causal …

Objective The increase in cardiovascular events (CVEs) in systemic lupus erythematosus
(SLE) is not fully explained by traditional risk factors. We previously identified four …